Our Strategy


At cureEDMD we are focused on finding treatments and, ultimately, cures for Emery-Dreifuss muscular dystrophy (EDMD).

We are currently pursuing two approaches for treatment, while facilitating a third approach. One approach is to identify medicines that are already available that would help in EDMD. There are tens of thousands of existing FDA-approved drugs and over-the-counter compounds, and it is often the case that a drug approved for one disease later proves to help with another. The other approach is to correct the underlying genetic causes of EDMD using gene therapy. Additionally, the research that cureEDMD helps to support might also lead to the development of new drugs specifically for EDMD.

Each approach offers different opportunities to move forward. While there is still much to learn and to do, advances in drug discovery, gene therapy, and genetics are creating new possibilities for the EDMD community.

1. Repurposing Existing Medicines

Could medicines already approved for other conditions help treat EDMD?

One promising approach is to explore whether existing medicines could be used to target the biological processes involved in EDMD.

Researchers first identify specific pathways or targets in heart and skeletal muscle cells that contribute to the disease. They then look for medicines that may influence those targets. These medicines are already approved by the FDA for other conditions.

Repurposing existing medicines could offer a faster and less costly path toward potential treatments than developing a completely new drug.

With support from cureEDMD-associated funding, meaningful progress has been made in identifying potential targets and advancing this work. The next steps include screening promising medicines to determine whether they show activity against EDMD-related disease processes.

New technologies, including artificial intelligence (AI), are also helping researchers explore potential drug candidates and identify promising connections between medicines and disease pathways.

2. Gene Therapy

Can we address the genetic changes that cause EDMD?

Gene therapy and other genetic approaches offer another important area of research. These strategies aim to address the underlying genetic changes responsible for EDMD.

For some forms of EDMD, researchers are exploring ways to deliver a working copy of a gene to affected cells. Other forms may require approaches that repair or modify the disease-causing gene or its effects.

For example, X-linked EDMD is commonly caused by changes in the EMD gene, which provides instructions for making a protein called emerin. Because the EMD gene is relatively small, it may be suitable for certain gene delivery approaches already being trialed for other genetic conditions.

Autosomal dominant EDMD is often associated with changes in the LMNA gene, which provides instructions for making the proteins lamin A and lamin C. Developing treatments for these forms may require different strategies, such as correcting the genetic change or addressing its harmful effects.

Research in other muscular dystrophies and genetic conditions provides valuable knowledge, technologies, and tools that can help advance gene therapy for EDMD.

These approaches offer the potential to address the root causes of the disease.

3. Developing New Treatments

What if existing medicines are not enough?

Some EDMD-related disease processes may require entirely new medicines designed specifically to target them.

Researchers can study how changes in the genes associated with EDMD affect cells and tissues, then identify other biological targets that may be involved in disease progression. These findings can help guide the development of new treatments.

Developing a new medicine takes substantial time, research, and investment. However, identifying promising disease targets is an important first step toward making this possible.

cureEDMD is helping to advance this work by supporting research, building scientific partnerships, and seeking opportunities to bring promising discoveries closer to treatment development.

Research into EDMD may also have implications for other muscular dystrophies and related conditions that share similar disease pathways. This broader potential could create additional opportunities for collaboration and investment from pharmaceutical and biotechnology companies.

Looking Ahead

Research and clinical progress are opening new doors for understanding EDMD and for potential treatments. By supporting multiple approaches and encouraging collaboration among scientists, clinicians, and industry partners, cureEDMD is working to help move promising discoveries forward.

Our goal is to turn scientific progress into meaningful advances for people living with EDMD.